Results 51 to 60 of about 7,902 (191)
Clinical efficacy and tolerability of olmesartan.
BACKGROUND Olmesartan medoxomil is an angiotensin II receptor antagonist that selectively and competitively inhibits the angiotensin II type 1 receptor.
Brunner HR, Hans R Brunner
core +1 more source
A novel series of candidate AT1 receptor antagonists based on oxadiazolone‐triazole scaffolds was designed and synthesized. Most compounds reduced angiotensin II‐induced vascular contraction in an initial biological screening, with compound 7f emerging as the most active derivative.
Larissa F. L. Ferreira +5 more
wiley +1 more source
Collagenous gastroduodenitis is a rare and may be associated with olmesartan, an angiotensin–II receptor antagonist used for management of hypertension. It is characterized by marked subepithelial collagen deposition with mucosal inflammatory infiltrate.
Pankaj Desai +5 more
doaj +1 more source
Olmesartan-induced Enteropathy: A Rare Side Effect of a Common Medication.
Ischemic heart disease and stroke are the leading causes of mortality worldwide according to the World Health Organization. Hypertension is a major factor in the development of these diseases.
Kurtkoti, Jagadeesh +9 more
core +1 more source
Metal‐Catalyzed Transformations of Carbon Dioxide Toward the Production of Commodity Chemicals
This perspective highlights how transition‐metal catalysis can enable the synthesis of economically attractive CO2‐derived commodity chemicals. By transforming waste CO2 into acrylic acid, cyclic carbonates, and other valuable products, these strategies provide a practical route for simultaneous CO2 sequestration and valorization, helping to align ...
Chaodi Dai +2 more
wiley +1 more source
Olmesartan medoxomil (OLM) is an ester prodrug of olmesartan (OL) developed to overcome the poor permeability of OL. OLM is an angiotensin receptor blocker and is commonly used to treat hypertension. However, OLM has low water solubility and low bioavailability of 26%. It is understood that OLM is unstable in aqueous media; however, this hydrolysis has
Lauren Landry, Xiaowei Dong
openaire +3 more sources
ABSTRACT Background and Aims Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, encompassing coronary artery disease, hypertension, heart failure, and cerebrovascular disorders. The global burden of CVD continues to rise, driven by complex interactions among endothelial dysfunction, oxidative stress, inflammation,
Nawfal Hasan Siam +8 more
wiley +1 more source
Olmesartan-induced enteropathy treated with budesonide
: Olmesartan, an angiotensin receptor blocker, is a widely spread antihypertensive drug. Seronegative vinous atrophy of the small intestine due to olmesartan use was first described in 2012.
Bogaert, J. +5 more
core +1 more source
ADMA, SDMA and L-arginine may be novel targets in pharmacotherapy for complications due to cardiopulmonary bypass [PDF]
Background: In this study, the effects of olmesartan therapy on asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), L-arginine and inducible nitric oxide synthase (iNOS) levels were investigated in patients undergoing cardiopulmonary ...
Kahraman Aydin +2 more
doaj
Evaluation and Comparison of Anticonvulsant Activity of Telmisartan and Olmesartan in Experimentally Induced Animal Models of Epilepsy [PDF]
Background: Epilepsy is one common neurological disorder requiring newer targets and newer drugs for its efficient management. In the recent days brain renin angiotensin system has gained immense importance because of its involvement in seizure ...
Pushpa V H +5 more
doaj +1 more source

